No abstract available
MeSH terms
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Antineoplastic Agents, Immunological / therapeutic use*
-
B7-H1 Antigen / antagonists & inhibitors
-
B7-H1 Antigen / genetics
-
B7-H1 Antigen / immunology
-
Carcinoma, Hepatocellular / drug therapy*
-
Carcinoma, Hepatocellular / genetics
-
Carcinoma, Hepatocellular / immunology
-
Carcinoma, Hepatocellular / pathology
-
Gene Expression Regulation, Neoplastic / drug effects*
-
Genome, Human
-
Humans
-
Immunotherapy, Adoptive / methods
-
Liver Neoplasms / drug therapy*
-
Liver Neoplasms / genetics
-
Liver Neoplasms / immunology
-
Liver Neoplasms / pathology
-
Phenylurea Compounds / therapeutic use
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors
-
Programmed Cell Death 1 Receptor / genetics
-
Programmed Cell Death 1 Receptor / immunology
-
Pyrazoles / therapeutic use
-
Quinolines / therapeutic use
-
Sunitinib / therapeutic use
-
T-Lymphocytes, Regulatory / cytology
-
T-Lymphocytes, Regulatory / drug effects
-
T-Lymphocytes, Regulatory / immunology
-
Transforming Growth Factor beta / antagonists & inhibitors
-
Transforming Growth Factor beta / genetics
-
Transforming Growth Factor beta / immunology
-
Tumor-Associated Macrophages / cytology
-
Tumor-Associated Macrophages / drug effects
-
Tumor-Associated Macrophages / immunology
Substances
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents, Immunological
-
B7-H1 Antigen
-
CD274 protein, human
-
PDCD1 protein, human
-
Phenylurea Compounds
-
Programmed Cell Death 1 Receptor
-
Pyrazoles
-
Quinolines
-
Transforming Growth Factor beta
-
LY-2157299
-
lenvatinib
-
avelumab
-
Sunitinib